LONDON (Reuters) - The World Health Organization (WHO) gave its backing on Wednesday to a new molecular test for tuberculosis made by Cepheid which can rapidly diagnose TB, one of the world's biggest ...

New agreement aims to provide greater access to millions more high-quality tuberculosis (TB) tests for people living in the least developed countries where the need is most urgent. Enables the Global ...

Sherlock Biosciences has teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech for new tests on the latter’s automated laboratory systems. The collaboration will focus on ...

Cepheid has supported TB testing worldwide for over 15 years. Xpert MTB/RIF, released in 2009 in collaboration with the Foundation for Innovative New Diagnostics (FIND), was a first-of-its-kind ...

These include fast, accurate, and easy to use tests for SARS-CoV-2, the virus causing COVID-19, Flu, MRSA, tuberculosis, and other HAI, sexual health, and oncology diseases. Each test is designed for ...

Cepheid 's CPHD rapid influenza and RSV assay - the Xpert Flu+RSV Xpress test - recently won the U.S. FDA 510(k) marketing approval and the Clinical Laboratory Improvement Achievements (CLIA) waiver.

SUNNYVALE, Calif., Dec. 8, 2022 /PRNewswire/ -- Currently circulating mutant strains of influenza highlight the need for multi-target diagnostic tests. Two recently identified mutations in the matrix ...

Cepheid's "Xpert Ebola" test will run on the company's GeneXpert system, which is already used to treat drug-resistant forms of tuberculosis.--Courtesy of Cepheid As diagnostics companies race to ...